NDAINJECTIONINJECTABLEPriority Review
Approved
Oct 2000
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
4
Data completeness
3/8 — Basic
Priority Review
NOVANTRONE (mitoxantrone hydrochloride) by Fresenius Kabi is clinical pharmacology: mechanism of action mitoxantrone, a dna-reactive agent that intercalates into deoxyribonucleic acid (dna) through hydrogen bonding, causes crosslinks and strand breaks. First approved in 2000.
Drug data last refreshed 13h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
Novantrone (mitoxantrone hydrochloride) is a DNA-intercalating topoisomerase II inhibitor administered intravenously for oncologic and immunologic indications. It causes DNA crosslinks and strand breaks while suppressing B cell, T cell, and macrophage proliferation. The drug exhibits cytocidal activity against both proliferating and nonproliferating cells, providing broad anti-cancer and immunosuppressive effects.
LOE Approaching
Product approaching loss of exclusivity with moderate competitive pressure; commercial teams should anticipate workforce transition planning and market share defense strategies.
Mechanism of Action
CLINICAL PHARMACOLOGY: Mechanism of Action Mitoxantrone, a DNA-reactive agent that intercalates into deoxyribonucleic acid (DNA) through hydrogen bonding, causes crosslinks and strand breaks. Mitoxantrone also interferes with ribonucleic acid (RNA) and is a potent inhibitor of topoisomerase II, an…
Worked on NOVANTRONE at Fresenius Kabi? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.